



Jaydeb Dey Research, [06-01-2022 16:59]

The Nifty ended 1.00% down at 17745.90. Taking negative global cues, it opened gap-down and remained range-bound till the end towards finishing off with a spinning-top candle. Gap-down opening after touching pull back high (=17945) suggesting staying cautious on rise in the price band of 17950-18050. The Nifty intraday range likely to be 17640-17950. Breaking down 17640 may unfold further decline.

On the Nifty hourly chart, leading indicators have reached over bought zone, suggesting upside is limited till 17950 as of now. Sharp weakness is likely below 17640.

Nifty patterns on multiple periods suggest; ending the session with a Spinning-top candle suggesting range-bound oscillation with a negative bias. Staying cautious on rise is advised.

Nifty Crucial Supports & Resistances-

Supports- 17640, 17500 Resistances- 17950, 18050

Open Positional Calls-

T+14 INST POSITIONAL SELL

| Futures Segment | UPL Jan Fut @ 770-775, TGT- 705, SL- closing above 810

T+10 INST POSITIONAL BUY

| Cash Segment | IPCA LAB @ 2160-2150, TGT- 2270, SL- closing below 2090

T+2 Positional Sell-

| Futures Segment | COAL IND Fut @ 154-155, TGT- 149, SL- closing above 158

Key Contents	Page No.
Domestic News	4

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks snapped a four-day winning streak, dragged by losses in information technology, banking, energy and realty stocks. This is the first time the S&P BSE Sensex and NSE Nifty have closed a session with losses in 2022.

Nifty index ended 1% lower at 17,746. The broader markets represented by the NIFTY 500 Index ended 0.69% lower, ending at 15,290. Among the sectorial indices Nifty Media was the top gainer, gaining by 0.91%, followed by Nifty Auto was gaining by 0.53%. Nifty IT was the top loser losing by 1.55%.

UPL was the top gainer, gaining by 2.39%, followed by Indusind Bank and Bajaj Auto gained by 1.96% & 1.78% respectively. JSW Steel was the top loser, losing by 2.96%, followed by Ultratech Cement and Tech Mahindra which fell by 2.62% & 2.62% respectively.

The Advance : Decline ratio stood at 1075:1041

Market Turnover (In Crore) 06-01-2022

Name	Last	Previous
NSE Cash	*NA	60259.42
NSE F&O	*NA	9983775.54
BSE Cash	4,681.65	4,673.30
BSE F&O	*NA	190.11

FII Derivatives Flow (In Crore) 06-01-2022

Instrument	Purchase	Sale	Net
Index Future	5220.09	8233.17	3013.08
Index Option	1357794.14	1343698.53	14095.61
Stock Future	11580.91	12829.99	1249.08
Stock Option	10366.10	10314.53	51.57

Institutional Flow (In Crore) 05-01-2022*

Institution	Purchase	Sale	Net
FII	7610.53	7273.7	336.83
DII	7001.1	5729.15	1271.95

*Data not updated till 6:30PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
UPL	2.39	4.83	5436867	1275834
Indusind Bank	1.96	4.10	5209239	6221103
Bajaj Auto	1.78	6.79	410181	333298
Bharti Airtel	1.49	4.57	21642414	4860011
Eicher Motors	1.39	10.17	1056323	1087678

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
RIL	2.15	2.43	6667483	6158588
Shree Cement	2.52	0.43	25411	23599
Tech Mahindra	2.62	5.99	4290750	2929475
Ultratech Cement	2.62	0.83	403448	293735
JSW Steel	2.96	4.36	4714784	3387583

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	59601.84	621.31	1.03	3.13	5.03	0.70	23.72
Nifty	17745.90	179.35	1.00	3.15	4.93	0.57	25.45
BSE M Cap	25336.55	11.48	0.05	2.87	1.99	0.15	35.14
BSE S Cap	29904.78	3.66	0.01	2.69	6.66	4.22	60.65
Nifty MC 100	30956.85	39.30	0.13	3.11	3.66	0.74	42.98
BSE Auto	25608.23	158.62	0.62	4.97	6.78	7.90	20.69
BSE Capgoods	29317.50	134.42	0.46	2.63	7.41	12.48	51.16
BSE FMCG	13855.10	90.51	0.65	1.79	2.67	6.31	9.42
BSE Metal	19745.20	113.55	0.57	4.75	5.79	2.22	60.28
BSE Oil&Gas	18232.52	61.51	0.34	5.35	4.28	4.05	26.39
BSE Healthcare	25716.85	162.45	0.63	1.06	4.10	1.48	16.81
BSE Power	3568.48	2.05	0.06	2.86	2.20	7.80	67.77
BSE Realty	3852.12	57.82	1.48	1.56	1.20	3.84	52.97
BSE ConsDur	45642.86	185.34	0.41	3.98	7.31	10.29	47.49
BSE Bank	42769.62	233.16	0.54	7.28	5.16	0.02	17.51
BSE IT	37134.40	523.15	1.39	1.79	8.65	7.51	47.43

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.73	0.03	1.65	14.92	20.86	13.99	67.40
UK	1.14	0.05	4.78	16.58	54.34	6.35	368.72
Brazil	4.76	0.10	2.06	4.62	2.72	8.41	44.17
Japan	0.12	0.04	44.19	74.65	175.56	47.62	490.48
Australia	1.87	0.08	4.48	14.49	17.89	15.84	74.95
India	6.53	0.02	0.28	1.12	2.63	3.97	11.50
Switzerland	0.04	0.02	28.85	72.39	87.58	72.18	92.43
Germany	0.05	0.04	41.67	72.32	87.37	73.08	90.58

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.50	0.14	0.19	0.11	1.24	0.65	1.86
USD Index	96.19	0.02	0.02	0.23	0.15	2.04	7.44
YUAN	6.38	0.01	0.21	0.07	0.02	1.06	1.34
GBP	1.35	0.00	0.23	0.20	1.98	0.41	0.60
EUR	1.13	0.00	0.03	0.12	0.23	2.12	8.24
YEN	115.81	0.30	0.26	0.63	2.01	3.80	11.03

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2289.00	4.00	0.18	0.22	29.24	59.47	60.63
Baltic Dirty	711.00	11.00	1.52	9.54	5.70	7.40	33.40
SG Dubai HY	6.52	0.48	7.95	16.64	3.33	14.19	685.54

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	36407.11	392.54	1.07	0.22	3.35	5.78	18.09
Nasdaq	15100.18	522.55	3.34	4.22	0.82	4.13	18.52
S&P 500	4700.58	92.96	1.94	1.93	2.37	7.72	25.41
FTSE100	7486.50	30.43	0.40	0.89	3.51	7.01	9.42
CAC40	7295.83	80.07	1.09	1.72	6.27	12.37	29.58
DAX	16126.01	148.45	0.91	1.71	4.83	7.68	16.06
Mexico IPC	53024.14	7.36	0.01	0.52	4.78	4.02	16.31
Brazil Bovespa	101005.6	2508.00	2.42	3.68	5.48	8.64	15.19
Russian RTS	1543.78	42.35	2.67	2.89	4.82	14.92	7.46
Japan Nikkei	28487.87	844.29	2.88	2.00	2.01	3.48	5.29
Hang Seng	23072.86	165.61	0.72	0.17	1.18	3.73	16.68
Taiwan Index	18367.92	132.04	0.71	0.66	3.84	12.05	22.59
Shanghai Comp	3586.08	9.10	0.25	0.30	0.09	0.50	0.99
KOSPI	2920.53	33.44	1.13	2.43	1.77	0.42	1.61
Malaysia KLCI	1533.36	14.59	0.94	0.66	3.36	1.67	3.68
Jakarta Comp	6653.35	8.95	0.13	0.80	1.62	3.68	9.69
Philippine SE	7085.52	5.88	0.08	2.76	0.63	0.40	0.53
Thai Exch	1653.03	23.76	1.42	0.70	4.08	2.07	10.77

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	79.02	1.17	1.50	2.64	13.71	2.05	56.07
BRENT Crude	81.89	1.08	1.34	2.95	12.64	3.78	59.36
Natural Gas	3.87	0.01	0.21	8.79	6.87	33.06	26.35

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1801.18	9.25	0.51	0.74	1.27	2.18	6.12
Silver(\$/Ounce)	22.34	0.47	2.06	3.07	0.22	1.28	18.15
Aluminium	2913.25	83.50	2.95	2.56	10.42	0.30	43.05
Copper	9708.25	80.25	0.82	1.18	2.34	5.79	21.44
Zinc	3624.00	31.75	0.87	1.92	11.84	19.44	30.08
Lead	2309.50	18.75	0.81	0.03	3.75	5.24	11.73

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	229.55	2.20	0.95	0.31	8.12	16.88	76.71
Cotton	115.75	0.53	0.46	1.23	8.17	7.01	50.66
Sugar	18.32	0.02	0.11	2.45	4.38	7.33	24.80
Wheat	755.00	5.75	0.76	3.17	6.36	0.53	15.49
Soybean	1377.75	17.00	1.22	2.93	8.78	9.24	22.22

Power CPSEs Capex rises 47% to Rs 40,000 cr in April-December

The power ministry the state-owned firms (CPSEs) under it have incurred capital expenditure of Rs 40,395.34 crore during April-December 2021, which is 47 per cent higher year-on-year. "CPSEs under Ministry of Power have incurred capital expenditure (Capex) of Rs 40,395.34 crore till the month of December during FY 2021-22. This is 47 per cent higher than the expenditure incurred during the corresponding period of FY 2020-21. Thus, the Capex performance of the ministry is significantly better compared to the previous year. It is to be noted that the CPSEs have also collectively met 80 per cent of the Capex target of FY 2021-22 - Rs 50,690.52 crore.

L&T Construction bags large contracts for water, effluent treatment business

L&T Construction's water and effluent treatment business has secured a slew of orders from various prestigious clients. The Department of Water Supply and Sanitation, Punjab, has awarded two EPC (engineering, procurement and construction) orders for the bulk supply of treated water to 10 lakh people in the Fazilka and Ferozepur districts of the state on a design-build-operate-transfer (DBOT) basis, Larsen & Toubro. The Department of Water Resources, Government of Odisha, has given a repeat EPC order to execute the Under Ground Pipeline Irrigation System for the Rengali Right Irrigation Project (Phase-I). The business has also secured add-on orders from the Uttar Pradesh State Water & Sanitation Mission to implement various rural water supply projects under the Jal Jeevan Mission to provide functional house tap connection (FHTC) in the state.

IRB Infrastructure arm executes concession pact for Rs 6,555 cr project in Uttar Pradesh

IRB Infrastructure Developers on its wholly-owned arm has executed a concession pact with Uttar Pradesh Expressways Industrial Development Authority (UPEIDA) for the Rs 6,555 crore 'Ganga Expressway' project in the state. The total length of the project is 129.7 km.

Alembic Pharma gets final nod from USFDA for generic drug to treat Parkinson's disease

Alembic Pharmaceuticals on Thursday said it has received final approval from the US health regulator for its generic Entacapone tablets indicated for patients with Parkinson's disease. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Entacapone tablets is for strength of 200 mg. It is therapeutically equivalent to the reference listed drug product (RLD) Comtan tablets, 200 mg, of Orion Corporation. Entacapone tablets are indicated as an adjunct to other medications, levodopa and carbidopa, to treat end-of-dose "wearing-off" in patients with Parkinson's disease. In the ongoing fiscal so far, the company said it has received 17 approvals (13 final approvals and 4 tentative approvals) and a cumulative total of 156 ANDA approvals (136 final approvals and 20 tentative approvals) from USFDA.

Aurobindo Pharma launches COVID-19 drug Molnupiravir in India

Aurobindo Pharma Limited has launched COVID-19 treatment drug Molnupiravir under brand name "Molnaflu" in India. Molnupiravir is for treatment of adult patients hospitalised with COVID-19, under certain conditions. Molnupiravir was earlier approved under Emergency Use Authorisation from the Central Drugs Standard Control Organisation. Earlier last year, Aurobindo had signed a bi-lateral non-exclusive voluntary licensing agreement with Merck Sharpe Dohme, Singapore (MSD), a subsidiary of Merck & Co. (US) to manufacture and supply Molnupiravir to over 100 low and middle-income countries (LMIC), including India. The company has adequate capacities to meet the global demand across the over 100 LMI Countries for the product.

Analyst Certification:

We /I, Jaydeb Dey and Deepankar Saha Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
